Monopar's ALXN1840 shows statistically significant copper balance improvement in Phase 2 Wilson disease trial
Monopar Therapeutics announced publication of Phase 2 study results demonstrating ALXN1840 (tiomolibdate choline) achieved statistically significant reductions in daily copper balance and increased fecal copper excretion in Wilson disease patients, with good tolerability. The pos
View filing at SEC.gov →